Following in the steps of US mRNA biotech Moderna (Nasdaq: MRNA), which last week gained a first regulator approval for its bivalent vaccine, now BioNTech (Nasdaq: BNTX) and Pfizer (NYSE: PFE) say they have completed their submission to the US Food and Drug Administration (FDA) today requesting an Emergency Use Authorization of a 30µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years and older.
The application is based on guidance from the FDA to include both clinical data from the companies’ bivalent Omicron BA.1-adapted vaccine and pre-clinical and manufacturing data from the bivalent Omicron BA.4/BA.5-adapted vaccine. This is aiming to address the continued evolution of SARS-CoV-2.
The companies have already generated mega-billion dollars-worth of sales with their COVID-19 vaccine Comirnaty.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze